Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18810362 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6 | August 2024 | May 2025 | Allow | 8 | 2 | 0 | No | No |
| 18674612 | DOSAGE OF CLAUDIN-6 CONJUGATES FOR CANCER TREATMENT | May 2024 | April 2025 | Allow | 11 | 2 | 0 | Yes | No |
| 18593028 | ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents | March 2024 | August 2024 | Allow | 5 | 0 | 0 | No | No |
| 18386421 | 5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-2-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 1 | 0 | Yes | No |
| 18316628 | IMMUNOTHERAPY TARGETING TUMOR NEOANTIGENIC PEPTIDES | May 2023 | August 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18057152 | ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF | November 2022 | March 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 17983727 | CANINE PARVOVIRUS NANOBODY CPV-VHH-E3 AND APPLICATION THEREOF | November 2022 | May 2023 | Allow | 6 | 0 | 0 | No | No |
| 18052738 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | November 2022 | March 2025 | Allow | 28 | 0 | 0 | No | No |
| 18052796 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | November 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 18051268 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2022 | February 2025 | Allow | 28 | 0 | 0 | No | No |
| 18051225 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2022 | February 2025 | Allow | 27 | 0 | 0 | No | No |
| 18050701 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2022 | April 2025 | Allow | 29 | 1 | 0 | No | No |
| 17959104 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | October 2022 | July 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17892460 | ANTI-CD20 ANTIBODY COMPOSITIONS | August 2022 | August 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17816114 | HUMAN MONOCLONAL ANTIBODIES AGAINST YELLOW FEVER VIRUS AND USES THEREFOR | July 2022 | March 2024 | Allow | 19 | 1 | 1 | No | No |
| 17840655 | Novel Tri-specific Binding Molecules | June 2022 | January 2025 | Allow | 31 | 2 | 1 | No | No |
| 17839754 | THERAPEUTIC METHODS AND COMPOSITIONS | June 2022 | June 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17837589 | Anti-TIGIT Antibodies | June 2022 | December 2024 | Allow | 30 | 0 | 0 | No | No |
| 17826295 | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY | May 2022 | December 2024 | Allow | 31 | 1 | 1 | No | No |
| 17736699 | BMA031 ANTIGEN BINDING POLYPEPTIDES | May 2022 | July 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17733918 | DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATE | April 2022 | September 2024 | Allow | 28 | 2 | 1 | No | No |
| 17732237 | ANTI-TUMOR DNA VACCINE WITH PD-1 AND LAG-3 PATHWAY BLOCKADE | April 2022 | May 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17717464 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A NECTIN-4 TARGETING AGENT | April 2022 | April 2024 | Allow | 24 | 2 | 1 | No | No |
| 17714912 | TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS | April 2022 | August 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17698426 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | March 2022 | May 2022 | Allow | 2 | 0 | 0 | No | No |
| 17696799 | BISPECIFIC AND MONOSPECIFIC ANTIBODIES USING NOVEL ANTI-PD-1 SEQUENCES | March 2022 | July 2024 | Allow | 28 | 0 | 0 | No | No |
| 17692315 | RADIOLABELLED ANTIBODY FRAGMENTS FOR USE IN TREATING CANCER | March 2022 | June 2025 | Allow | 39 | 2 | 0 | No | No |
| 17690702 | HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6 | March 2022 | June 2023 | Allow | 15 | 0 | 0 | Yes | No |
| 17580728 | VACCINE COMPOSITIONS COMPRISING AN AMPHIPATHIC COMPOUND, A NEOANTIGEN AND A HYDROPHOBIC CARRIER, AND METHODS OF USE THEREOF | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17580241 | METHODS FOR TREATING BREAST AND OTHER CANCERS BY TARGETING ARGININOSUCCINATE SYNTHETASE 1-DEFICIENCY | January 2022 | January 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17627540 | CLAUDIN18 ANTIBODIES AND METHODS OF TREATING CANCER | January 2022 | February 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17561415 | HIGH-AFFINITY ANTI-MERTK ANTIBODIES AND USES THEREOF | December 2021 | December 2024 | Allow | 36 | 1 | 0 | No | No |
| 17645391 | CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17545274 | COMBINATIONS AND USES THEREOF | December 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17537837 | METHODS AND COMPOSITIONS FOR REDUCING METASTASES | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17534315 | LAG-3 BINDING MEMBERS | November 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17533230 | BINDING MOLECULES BINDING PD-L1 AND LAG-3 | November 2021 | November 2024 | Allow | 36 | 1 | 0 | No | No |
| 17531473 | CYTOKINE PROFILING ANALYSIS | November 2021 | September 2024 | Allow | 34 | 1 | 1 | No | No |
| 17530510 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | November 2021 | May 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17524894 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | November 2021 | December 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17519192 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | November 2021 | February 2024 | Allow | 27 | 0 | 0 | No | No |
| 17519436 | Antibodies binding To HLA-A2/WT1 | November 2021 | May 2024 | Allow | 31 | 1 | 0 | No | No |
| 17517994 | CH3 DOMAIN VARIANT PAIR INDUCING FORMATION OF HETERODIMER OF HEAVY CHAIN CONSTANT REGION OF ANTIBODY AT HIGH EFFICIENCY, METHOD FOR PREPARING SAME, AND USE THEREOF | November 2021 | February 2025 | Allow | 40 | 1 | 0 | No | No |
| 17514743 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2021 | January 2024 | Allow | 26 | 0 | 0 | No | No |
| 17514599 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | October 2021 | March 2024 | Allow | 29 | 1 | 0 | No | No |
| 17515010 | KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS | October 2021 | July 2022 | Allow | 8 | 2 | 0 | No | No |
| 17510738 | Tandem Diabody for CD16A-directed NK-cell Engagement | October 2021 | December 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17503038 | ANTI-CD38 ANTIBODIES AND METHODS OF USE | October 2021 | February 2022 | Allow | 4 | 0 | 0 | Yes | No |
| 17499814 | ANTI-CD147 ANTIBODY | October 2021 | May 2022 | Allow | 7 | 1 | 0 | No | No |
| 17498418 | BIOSYNTHETIC MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17493266 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | October 2021 | March 2025 | Allow | 41 | 2 | 1 | No | No |
| 17492111 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | October 2021 | January 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17479776 | COMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS | September 2021 | October 2022 | Allow | 13 | 2 | 0 | Yes | No |
| 17446943 | BISPECIFIC ANTIBODIES SPECIFIC FOR PD1 AND TIM3 | September 2021 | April 2025 | Allow | 43 | 1 | 0 | No | No |
| 17466922 | IGA FC-FOLATE CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER | September 2021 | August 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17403698 | BAFF-R ANTIBODIES AND USES THEREOF | August 2021 | January 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17402068 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | August 2021 | September 2024 | Allow | 37 | 0 | 0 | No | No |
| 17388059 | SIGLEC NEUTRALIZING ANTIBODIES | July 2021 | July 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17384110 | Bioengineered Microbial Spores | July 2021 | April 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17382305 | METHODS AND SYSTEMS FOR GENERATING COMPLEX SPATIAL PATTERNS | July 2021 | January 2025 | Allow | 42 | 1 | 0 | No | No |
| 17304702 | BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA | June 2021 | November 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17304683 | BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA | June 2021 | June 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17312311 | Saponin Conjugates | June 2021 | January 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17334151 | COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER | May 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17324508 | ANTI-PD-1 ANTIBODIES AND COMPOSITIONS | May 2021 | February 2024 | Allow | 33 | 0 | 1 | No | No |
| 17318310 | HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS | May 2021 | December 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17314492 | PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS | May 2021 | November 2023 | Allow | 30 | 1 | 0 | No | No |
| 17309144 | ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF | April 2021 | May 2025 | Allow | 49 | 1 | 1 | No | No |
| 17290172 | METHODS FOR PREDICTING A RESPONSE TO BEVACIZUMAB OR PLATINUM-BASED CHEMOTHERAPY OR BOTH IN PATIENTS WITH OVARIAN CANCER | April 2021 | February 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17286437 | ANTI-CLAUDIN 18.2 AND ANTI-4-IBB BISPECIFIC ANTIBODIES AND USES THEREOF | April 2021 | December 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 17286406 | ANTIBODIES AND METHODS FOR TREATMENT OF LYSSAVIRUS INFECTION | April 2021 | March 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17232537 | MULTISPECIFIC ANTIBODIES | April 2021 | August 2023 | Allow | 28 | 0 | 0 | No | No |
| 17284599 | Novel method and compounds for treatment of cognitive loss associated with adult onset leukodystrophy with axonal spheroids and pigmented glia (ALSP) and other neurodegenerative diseases involving reduced colony stimulating factor-1 receptor (CSF-1R) signaling | April 2021 | May 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17228213 | METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF | April 2021 | October 2024 | Abandon | 43 | 2 | 1 | Yes | No |
| 17284427 | COMPOSITIONS AND METHODS FOR PREVENTING OR AMELIORATING NEONATAL HSV INFECTION | April 2021 | April 2025 | Allow | 48 | 2 | 1 | No | No |
| 17226006 | METHODS AND COMPOSITIONS FOR TREATING CANCER | April 2021 | February 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17224431 | METHODS OF DETECTING AND REDUCING CANCER CELL CENTRAL NERVOUS SYSTEM COLONIZATION | April 2021 | December 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17210860 | COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER | March 2021 | April 2024 | Allow | 37 | 2 | 0 | No | No |
| 17277214 | CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE | March 2021 | November 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17274960 | MEDICINAL COMPOSITION CONTAINING MONOCLONAL ANTIBODY OR ANTIBODY FAB FRAGMENT THEREOF, AND USE THEREOF | March 2021 | August 2024 | Allow | 41 | 1 | 1 | No | No |
| 17250832 | CANCER TREATMENT WITH 237 CAR-T CELL BASED THERAPEUTICS RECOGNIZING THE TN EPITOPE | March 2021 | April 2025 | Allow | 49 | 1 | 1 | No | No |
| 17180110 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | February 2021 | September 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 17172577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | February 2021 | August 2023 | Allow | 31 | 1 | 0 | No | No |
| 17172621 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | February 2021 | September 2023 | Allow | 31 | 1 | 0 | No | No |
| 17172252 | Targeted Immunotolerance | February 2021 | July 2024 | Allow | 41 | 2 | 1 | No | No |
| 17161586 | CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | January 2021 | July 2021 | Allow | 5 | 1 | 0 | No | No |
| 17148309 | METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 | January 2021 | July 2023 | Allow | 31 | 0 | 1 | No | No |
| 17143204 | Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof | January 2021 | May 2025 | Allow | 52 | 1 | 1 | No | No |
| 17140996 | TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES | January 2021 | March 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17138279 | ANTI-CD73 ANTIBODIES AND USES THEREOF | December 2020 | October 2023 | Allow | 34 | 1 | 1 | No | No |
| 17138403 | ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | December 2020 | August 2023 | Allow | 32 | 1 | 0 | No | No |
| 17138306 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | December 2020 | November 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17134828 | Glycan-dependent Immunotherapeutic Molecules | December 2020 | January 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17135170 | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF | December 2020 | January 2024 | Abandon | 37 | 0 | 1 | No | No |
| 17126838 | FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIES | December 2020 | March 2023 | Allow | 27 | 0 | 0 | No | No |
| 17253286 | METHOD FOR PRODUCING A CONTROLLED MIXTURE OF TWO OR MORE DIFFERENT ANTIBODIES | December 2020 | November 2024 | Allow | 46 | 1 | 1 | No | No |
| 17120935 | Antibodies Specific for CD47, PD-L1, and Uses Thereof | December 2020 | February 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17119753 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | December 2020 | January 2023 | Allow | 25 | 0 | 0 | No | No |
| 17117969 | ANTI-TIGIT ANTIBODIES AND USES THEREOF | December 2020 | February 2021 | Allow | 2 | 0 | 0 | Yes | No |
| 17108076 | Modified Cell Expansion and Uses Thereof | December 2020 | July 2024 | Allow | 43 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOSELEY II, NELSON B.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOSELEY II, NELSON B works in Art Unit 1642 and has examined 713 patent applications in our dataset. With an allowance rate of 67.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner MOSELEY II, NELSON B's allowance rate of 67.9% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOSELEY II, NELSON B receive 1.59 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MOSELEY II, NELSON B is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +43.8% benefit to allowance rate for applications examined by MOSELEY II, NELSON B. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 59.1% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 76.0% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 94.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 53% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.